Extendicare (OTCMKTS:EXETF – Get Free Report) is expected to release its results before the market opens on Thursday, February 26th. Analysts expect Extendicare to post earnings of $0.1928 per share and revenue of $519.80 million for the quarter.
Extendicare Stock Performance
Shares of EXETF opened at $18.72 on Wednesday. The business has a fifty day moving average of $16.74 and a 200 day moving average of $13.55. Extendicare has a 52-week low of $8.04 and a 52-week high of $18.72.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on EXETF shares. TD Securities restated a “hold” rating on shares of Extendicare in a report on Friday, November 14th. BMO Capital Markets raised shares of Extendicare from a “market perform” rating to an “outperform” rating in a research report on Thursday, December 4th. Royal Bank Of Canada upgraded Extendicare from a “sector perform” rating to an “outperform” rating in a research report on Thursday, December 4th. Finally, National Bank Financial reiterated an “outperform” rating on shares of Extendicare in a report on Thursday, December 4th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy”.
Extendicare Company Profile
Extendicare Inc (OTCMKTS:EXETF) is a Canada-based senior care provider headquartered in Markham, Ontario. The company specializes in the ownership and operation of long-term care homes, retirement residences and home health care services. It is publicly listed on the Toronto Stock Exchange under the symbol EXE and trades in the over-the-counter market as EXETF.
Extendicare’s operations are organized into two primary segments. The Long-Term Care & Retirement Living division operates approximately 120 facilities under the Extendicare and EspritVitalité banners, serving residents in Ontario, Alberta, Saskatchewan and parts of Atlantic Canada.
Further Reading
- Five stocks we like better than Extendicare
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- This makes me furious
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
